Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by plantrader on Jan 31, 2023 1:27pm

JV vs Buyout

If the co enters into a JV, what does that mean for the prospects of a future buyout? Does it mean the buyout can only occur with the same company that entered into the JV? I assume that would be part of the terms of a JV, nobody else has a shot at buying Theralase out? Is this considered a limiting factor in such a way that a JV isn't always best for maximixing buyout/$$ potential? 

I realize the company needs the funding that comes along with a JV, regardless, and possibly the expertise and sway with the FDA as well. Just trying to understand some of the limitations that a JV might introduce.
Comment by ggrellette on Jan 31, 2023 3:01pm
When a JV occurs there are conditions in the agreement. The JV partner will have to right to match any offers should a buyout be offered. This would certainly be one of the conditions.
Comment by plantrader on Jan 31, 2023 3:18pm
@ggrel, Thanks for the info. Sounds like that means a JV with one big pharma doesn't usually prevent other big pharma from being able to make a buyout offer. That's mainly what I was wondering about. Good to know.
Comment by Yajne on Jan 31, 2023 7:15pm
I tend to agree with ggrellette...the clause in often referred to as 'most favored nations clause' which gives the right to match any offer. 
Comment by Legit62 on Jan 31, 2023 7:32pm
This sounds like there very well could be a bidding war amongst the big boys, and we will be on winning end, our time is getting near , February here tomorrow and soon Roger will be back
Comment by Legit62 on Jan 31, 2023 7:34pm
Look back into all the shares he and insiders got recently, lot of their own funds spent, for a reason of course
Comment by ScienceFirst on Jan 31, 2023 5:16pm
No.   Many biotechs have deals with different big pharmas before being taken over by a big pharma. It can only be positive and even start a bidding war as more big pharmas can realize how good is the scientific platform.
Comment by CancerSlayer on Feb 01, 2023 1:13am
  Once Pharma & specialists (oncologists/surgeons) see success using our unique drug, it should have a snowball effect on other suitable indications imo.   Photofrin PDT had set a relatively low standard in view of its lower selectivity, dark toxicity & other adverse side effects (i.e. weeks/months of photosensitivity).  Because of the above, both surgical & ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250